Skip to content
Luna Metabolic
Menu

Evidence review

Compounded vs Brand-Name GLP-1 for Women

What the compounded-vs-brand choice really means for women: what the evidence covers, what compounding is, and how to decide with a clinician.

By The Luna Editorial Team, Women's Metabolic Health Desk

What each option actually is

Brand-name GLP-1 medicines — semaglutide sold as Wegovy, tirzepatide sold as Zepbound — are the exact products studied in the large clinical trials and reviewed by the FDA3. Compounded versions are made by pharmacies that prepare a medication to order. The FDA does not review or approve compounded drugs the way it does brand-name ones, and it has publicly flagged quality and dosing concerns with some compounded GLP-1 products45. That difference in oversight is the heart of the choice, and it is why this decision is worth making with a clinician rather than on price alone. This guide is educational only and not medical advice.

What the evidence does and does not cover

The efficacy numbers women see quoted come from brand-name products: about 15% mean weight loss with once-weekly semaglutide in STEP 11 and around 20% with tirzepatide in SURMOUNT-12. Those trials studied specific molecules at specific doses under monitoring. Compounded preparations are not the same as the trial product, so the published results do not automatically transfer to them. This matters for women who are making a real health decision on the strength of those numbers — the data belongs to the approved products.

Why the women's-health lens changes the weighting

For a woman with PCOS, in perimenopause, or relying on the pill, the value of a program is not only the drug in the vial — it is the oversight around it: labs, titration support, and someone who understands how a GLP-1 interacts with your hormones and contraception. Compounding can lower cost, and for some women cost is the deciding barrier to any treatment at all. But the trade-off is real, and a program that leans on compounding should still provide genuine clinical oversight, transparent sourcing, and a licensed prescriber — the factors our Luna Fit Score methodology rewards.

How to decide

Ask which specific product you would receive and from what kind of pharmacy; whether a licensed clinician oversees dosing and follow-up; and what the total monthly cost is either way. If a program cannot answer plainly, that is an answer. Our cost and safe-start guide explains the 503A and 503B pharmacy distinctions in more depth, and our provider-choice checklist walks through the rest of the conversation. Whichever route you choose, choose it with a clinician who can see your whole picture.

Frequently asked questions

Do trial results apply to compounded GLP-1?

The published weight-loss figures come from brand-name products studied under monitoring. Compounded preparations are not the same as the trial product, so those results do not automatically transfer. Discuss the difference with a clinician.

Is compounded GLP-1 safe for women?

Compounded drugs are not FDA-reviewed the way brand-name ones are, and the FDA has flagged quality and dosing concerns with some products. If you consider a compounded route, insist on a licensed prescriber, transparent sourcing and real oversight.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2032183
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2206038
  3. U.S. Food and Drug Administration (2023). Wegovy (semaglutide) injection — prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
  4. U.S. Food and Drug Administration (2024). Compounding and the FDA: Questions and Answers. FDA. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  5. U.S. Food and Drug Administration (2024). Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss. FDA. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Continue reading